|
62 Companies |
|
89 Products |
|
89 Products |
|
76 Mechanisms of Action |
|
2 Trials |
|
652 News |
|
| «12345678910111213...1314» |
- | Trial completion, Enrollment change: Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others (clinicaltrials.gov) - Jun 21, 2017
P=N/A, N=21, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | N=60 --> 21
- | Trial primary completion date, Surgery: Complications of Endocrine Surgery: Data From the United HealthSystem Consortium (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=1000, Active, not recruiting, Sponsor: University of Arkansas
Active, not recruiting --> Completed | N=60 --> 21 Trial primary completion date: Dec 2017 --> Dec 2018
- | thalidomide / Generic mfg.
Trial completion: Thalidomide in Treating Patients With Thyroid Cancer (clinicaltrials.gov) - Jun 6, 2017
P2, N=0, Completed, Sponsor: Kenneth Ain
Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed
- | Trial completion: Thyroid Disease Serum Repository (clinicaltrials.gov) - Jun 2, 2017
P=N/A, N=1000, Completed, Sponsor: University of Arkansas
Active, not recruiting --> Completed Suspended --> Completed
- | gefitinib / Generic mfg.
Enrollment change, Metastases: Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy (clinicaltrials.gov) - May 31, 2017
P2, N=27, Completed, Sponsor: Massachusetts General Hospital
Suspended --> Completed N=38 --> 27
- | Trial completion, Surgery: Comparing Harmonic Ultrasonic Scalpel to Small Jaw Bipolar Device in Thyroid Surgery (clinicaltrials.gov) - May 22, 2017
P=N/A, N=100, Completed, Sponsor: National Cancer Centre, Singapore
N=38 --> 27 Active, not recruiting --> Completed
- | Enrollment change: LL-PTC: Leptin Levels in Papillary Thyroid Cancer (clinicaltrials.gov) - May 11, 2017
P=N/A, N=18, Completed, Sponsor: University of Nebraska
Active, not recruiting --> Completed N=150 --> 18
- | pioglitazone / Generic mfg.
Trial completion, Enrollment change: Pioglitazone in Thyroid Cancers (clinicaltrials.gov) - May 11, 2017
P2, N=1, Completed, Sponsor: University of Michigan
N=150 --> 18 Recruiting --> Completed | N=15 --> 1
- | Trial completion, Phase classification, Trial primary completion date: Low Level Laser Therapy for Autoimmune Thyroiditis (clinicaltrials.gov) - May 5, 2017
P=N/A, N=43, Completed, Sponsor: University of Sao Paulo General Hospital
Recruiting --> Completed | N=15 --> 1 Active, not recruiting --> Completed | Phase classification: P2/3 --> PN/A | Trial primary completion date: Nov 2015 --> Mar 2016
- | Trial primary completion date: The Reduced Thyroid Function of the Premature Newborn: Relation With Molecular Changes in the Placenta and Maternal Thyroid Hormone Status and Neurodevelopmental Implications (clinicaltrials.gov) - May 3, 2017
P=N/A, N=319, Completed, Sponsor: Universitaire Ziekenhuizen Leuven
Active, not recruiting --> Completed | Phase classification: P2/3 --> PN/A | Trial primary completion date: Nov 2015 --> Mar 2016 Trial primary completion date: Oct 2013 --> Apr 2014
- | azithromycin / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date, Immunomodulating: Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy (clinicaltrials.gov) - Apr 27, 2017
P1/2, N=0, Withdrawn, Sponsor: Rabin Medical Center
Trial primary completion date: Oct 2013 --> Apr 2014 N=14 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Jul 2012 --> Nov 2014
- | NN1213 / Novo Nordisk
Trial completion: Subclinical Thyroid Dysfunction and Risk of Myocardial Infarction and Stroke (clinicaltrials.gov) - Apr 24, 2017
P=N/A, N=3200, Completed, Sponsor: University of North Carolina, Chapel Hill
N=14 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Jul 2012 --> Nov 2014 No longer recruiting --> Completed
- | Trial completion, Enrollment change: Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo (clinicaltrials.gov) - Apr 10, 2017
P=N/A, N=3258, Completed, Sponsor: St. Luke's-Roosevelt Hospital Center
No longer recruiting --> Completed Recruiting --> Completed | N=1500 --> 3258
- | Trial completion: Post-Radioiodine Graves' Management: The PRAGMA-Study (clinicaltrials.gov) - Mar 30, 2017
P=N/A, N=803, Completed, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Recruiting --> Completed | N=1500 --> 3258 Recruiting --> Completed
- | vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 22, 2017
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- | Trial completion, Enrollment change: Thyroid Hormone Replacement for Subclinical Hypothyroidism (clinicaltrials.gov) - Mar 13, 2017
P4, N=737, Completed, Sponsor: NHS Greater Glasgow and Clyde
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed | N=540 --> 737
- buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment closed, Enrollment change, Metastases: A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies (clinicaltrials.gov) - Mar 3, 2017
P1, N=43, Active, not recruiting, Sponsor: Emory University
Recruiting --> Completed | N=540 --> 737 Recruiting --> Active, not recruiting | N=63 --> 43
- || buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date, Metastases: A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies (clinicaltrials.gov) - Feb 15, 2017
P1, N=63, Recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting | N=63 --> 43 Trial primary completion date: Feb 2017 --> Feb 2018
- Trial primary completion date: The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer (clinicaltrials.gov) - Feb 11, 2017
P=N/A, N=120, Recruiting, Sponsor: Cyprus University of Technology
Trial primary completion date: Feb 2017 --> Feb 2018 Trial primary completion date: Dec 2016 --> Sep 2017
- NN1213 / Novo Nordisk
Trial completion, Trial primary completion date: Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities (clinicaltrials.gov) - Feb 7, 2017
P2, N=157, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Trial primary completion date: Dec 2016 --> Sep 2017 Suspended --> Completed | Trial primary completion date: Jan 2099 --> Feb 2017
- Trial primary completion date, Surgery: Complications of Endocrine Surgery: Data From the United HealthSystem Consortium (clinicaltrials.gov) - Jan 5, 2017
P=N/A, N=1000, Active, not recruiting, Sponsor: University of Arkansas
Suspended --> Completed | Trial primary completion date: Jan 2099 --> Feb 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- Torisel (temsirolimus) / Pfizer
Trial primary completion date: Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer (clinicaltrials.gov) - Jan 5, 2017
P2, N=40, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial primary completion date, IO biomarker: Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (clinicaltrials.gov) - Dec 23, 2016
P2, N=25, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Aug 2016 --> Jun 2017
- Trial termination: Central Compartment Neck Dissection With Thyroidectomy (clinicaltrials.gov) - Dec 14, 2016
P=N/A, N=128, Terminated, Sponsor: University of Alberta
Trial primary completion date: Aug 2016 --> Jun 2017 Recruiting --> Terminated; Poor patient accrual
- | Trial completion: Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer (clinicaltrials.gov) - Nov 29, 2016
P2/3, N=74, Completed, Sponsor: University Health Network, Toronto
Recruiting --> Terminated; Poor patient accrual Active, not recruiting --> Completed
- ||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Trial initiation date: Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease (clinicaltrials.gov) - Nov 25, 2016
P2, N=84, Active, not recruiting, Sponsor: River Vision Development Corporation
Active, not recruiting --> Completed Initiation date: Apr 2013 --> Jul 2013
- Trial completion: Polymorphisms in the Vitamin D System and Health (clinicaltrials.gov) - Nov 14, 2016
P=N/A, N=9700, Completed, Sponsor: University of Tromso
Initiation date: Apr 2013 --> Jul 2013 Active, not recruiting --> Completed
- | gefitinib / Generic mfg.
Trial completion, Metastases: Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy (clinicaltrials.gov) - Nov 4, 2016
P2, N=38, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Clinical protocol, Trial completion, Trial primary completion date: Intra-operative Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery (clinicaltrials.gov) - Nov 2, 2016
P1/2, N=41, Completed, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jun 2016
- thyroxine / Generic mfg.
Enrollment change, Trial withdrawal: Effects of Levothyroxine Treatment on Hemodynamic and Renal Functions in Subclinical Hypothyroidism (clinicaltrials.gov) - Oct 28, 2016
P4, N=0, Withdrawn, Sponsor: Centre Hospitalier Universitaire de Nice
Recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jun 2016 N=16 --> 0 | Recruiting --> Withdrawn
- Enrollment change: The TRUST Study - Depression Substudy (clinicaltrials.gov) - Oct 21, 2016
P4, N=450, Recruiting, Sponsor: University Hospital Inselspital, Berne
N=16 --> 0 | Recruiting --> Withdrawn N=1500 --> 450
- Trial completion, Trial primary completion date: Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy (clinicaltrials.gov) - Oct 18, 2016
P=N/A, N=50, Completed, Sponsor: University of Nebraska
N=1500 --> 450 Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Feb 2016
- Trial completion, Trial primary completion date: MyEndo-Thyroid: Thyroid Disorders in Malaysia: A Nationwide Multicentre Study (clinicaltrials.gov) - Oct 18, 2016
P=N/A, N=2498, Completed, Sponsor: International Islamic University Malaysia
Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Feb 2016 Enrolling by invitation --> Completed | Trial primary completion date: May 2016 --> Sep 2016
- irinotecan / Generic mfg.
Enrollment change, Metastases: Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer (clinicaltrials.gov) - Oct 14, 2016
P2, N=6, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Enrolling by invitation --> Completed | Trial primary completion date: May 2016 --> Sep 2016 N=33 --> 6
- | irinotecan / Generic mfg.
Trial completion, Metastases: Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer (clinicaltrials.gov) - Oct 13, 2016
P2, N=6, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=33 --> 6 Recruiting --> Completed
- Trial primary completion date: Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH) (clinicaltrials.gov) - Oct 12, 2016
P=N/A, N=30, Recruiting, Sponsor: Washington Hospital Center
Recruiting --> Completed Trial primary completion date: Jul 2012 --> Jun 2019
- Trial completion: Galectin 3 Dosage in Diagnosis of Nodular and Multinodular Goiter (clinicaltrials.gov) - Oct 10, 2016
P=N/A, N=193, Completed, Sponsor: University Hospital, Rouen
Trial primary completion date: Jul 2012 --> Jun 2019 Active, not recruiting --> Completed
- Trial completion: APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS. (clinicaltrials.gov) - Sep 22, 2016
P=N/A, N=25, Completed, Sponsor: Corporacion Parc Tauli
Active, not recruiting --> Completed Recruiting --> Completed
- | carbimazole / Generic mfg., propylthiouracil / Generic mfg.
Trial completion, Enrollment change: Antithyroid Drug Treatment of Thyrotoxicosis in Young People (clinicaltrials.gov) - Sep 21, 2016
P3, N=81, Completed, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Recruiting --> Completed Active, not recruiting --> Completed | N=160 --> 81
- Trial primary completion date, MRI: Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=20, Suspended, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | N=160 --> 81 Trial primary completion date: Dec 2015 --> Apr 2015
- Trial completion: Color Flow Doppler Ultrasound in Subclinical Thyroid Dysfunction (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=60, Completed, Sponsor: HaEmek Medical Center, Israel
Trial primary completion date: Dec 2015 --> Apr 2015 Not yet recruiting --> Completed
- Trial termination: LPSH: Lipids Profile in Subclinical Hypothyroidism (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=100, Terminated, Sponsor: HaEmek Medical Center, Israel
Not yet recruiting --> Completed Not yet recruiting --> Terminated; Recruiting difficulties
- Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Trial completion, Enrollment change, Trial primary completion date: Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine (clinicaltrials.gov) - Sep 6, 2016
P2, N=39, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Terminated; Recruiting difficulties Active, not recruiting --> Completed | N=32 --> 39 | Trial primary completion date: Apr 2018 --> Aug 2016
- Trial primary completion date: Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy (clinicaltrials.gov) - Aug 31, 2016
P=N/A, N=40, Enrolling by invitation, Sponsor: University of Chicago
Active, not recruiting --> Completed | N=32 --> 39 | Trial primary completion date: Apr 2018 --> Aug 2016 Trial primary completion date: Jan 2016 --> Jan 2018
- | sorafenib / Generic mfg.
Trial completion, Metastases: Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients (clinicaltrials.gov) - Aug 29, 2016
P2, N=18, Completed, Sponsor: Bayer
Trial primary completion date: Jan 2016 --> Jan 2018 Active, not recruiting --> Completed
- Enrollment change, Real-world evidence, Real-world: MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use (clinicaltrials.gov) - Aug 16, 2016
P=N/A, N=907, Completed, Sponsor: University of Missouri-Columbia
Active, not recruiting --> Completed N=728 --> 907
- Trial primary completion date: The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer (clinicaltrials.gov) - Jul 28, 2016
P=N/A, N=120, Recruiting, Sponsor: Cyprus University of Technology
N=728 --> 907 Trial primary completion date: May 2016 --> Dec 2016
- Trial primary completion date: Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others (clinicaltrials.gov) - Jul 26, 2016
P=N/A, N=60, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: Jun 2016 --> Jun 2017
- Enrollment change, Trial termination, Trial primary completion date, Metastases: DOSIMETA: Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer (clinicaltrials.gov) - Jul 13, 2016
P=N/A, N=4, Terminated, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Trial primary completion date: Jun 2016 --> Jun 2017 N=35 --> 4 | Recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Jun 2016; Recruitment difficulties
- NN1213 / Novo Nordisk
Enrollment change, Trial suspension: Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities (clinicaltrials.gov) - Jul 6, 2016
P2, N=157, Suspended, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
N=35 --> 4 | Recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Jun 2016; Recruitment difficulties N=999999 --> 157 | Recruiting --> Suspended